Abbvie, Author Interviews, OBGYNE, Pain Research / 26.07.2018
ORILISSA™ (elagolix) Now Approved for Management of Moderate to Severe Pain Associated with Endometriosis
MedicalResearch.com Interview with:
Dr. Dawn Carlson MD MPH
Vice President, General Medicine Development
AbbVie
MedicalResearch.com: Please provide some background on this announcement. Would you briefly explain what endometriosis is? Whom does it affect and how does it interfere with quality of life?
Response: Endometriosis is one of the most common gynecologic disorders in the U.S that affects an estimated one in 10 women of reproductive age. It occurs when tissue similar to the lining of the uterus starts growing outside of the uterus, where it doesn’t belong.
The symptoms of endometriosis, including pain with menstrual periods and between periods, and with sexual intercourse, can be debilitating and significantly impact day-to-day activities of women’s lives, personally and professionally. Unfortunately, women with endometriosis can suffer for up to 10 years and visit multiple physicians before receiving a proper diagnosis. Unresolved endometriosis pain results in higher healthcare costs from emergency department visits and repeat surgeries. (more…)